18.06.2015 Views

Web-economic-crisis-health-systems-and-health-web

Web-economic-crisis-health-systems-and-health-web

Web-economic-crisis-health-systems-and-health-web

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

20 Economic <strong>crisis</strong>, <strong>health</strong> <strong>systems</strong> <strong>and</strong> <strong>health</strong> in Europe: country experience<br />

for medical specialists who have not signed the agreement to charge supplements<br />

for day-stay care. However, the National Committee of Representatives of<br />

Physicians <strong>and</strong> Sickness Funds recommends that medical specialists do not<br />

charge supplements to patients with preferential reimbursement, chronically ill<br />

patients <strong>and</strong> for day-stay care in oncology.<br />

3.3 Changes to <strong>health</strong> service planning, purchasing <strong>and</strong> delivery<br />

There also have been efforts to protect access to the <strong>health</strong> care system by<br />

policies intended to control volume or prices. Such policies mainly have been<br />

implemented in the pharmaceutical sector: 42% of all savings in 2012–2013<br />

were realized in this sector (Gillis, 2014).<br />

Policies affecting <strong>health</strong> system input prices<br />

Pharmaceuticals<br />

A wide variety of measures have been taken to reduce input prices, particularly<br />

of pharmaceuticals (Table 1.4). Although these measures were part of ongoing<br />

reforms, they have been intensified in recent years. They have contributed<br />

to decreases in public pharmaceutical spending as a proportion of total<br />

<strong>health</strong> spending.<br />

Table 1.4 Pharmaceutical prescribing, pricing <strong>and</strong> reimbursement policies in Belgium<br />

Policy<br />

Measure a<br />

Generic policy changes<br />

Reference price level<br />

Percentage reduction in the ex-factory price of the original drug of<br />

31% (gradual increase since 2001)<br />

Additional reductions for drugs in reimbursement category A (no<br />

co-payment) (2012)<br />

Generic substitution For acute treatments with an antibiotic or antifungal (May 2012)<br />

Minimum prescription<br />

of low-cost drugs<br />

INN prescription<br />

Price cuts<br />

Linear price cuts<br />

International price<br />

comparison<br />

Taxes<br />

Increase of quota (2011)<br />

Obligation to dispense a drug among the group of cheapest drugs<br />

for every INN prescription (April 2012)<br />

Reduction of reimbursement basis for old drugs since 2010; price<br />

cut of 1.95% in April 2012 <strong>and</strong> April 2013<br />

Reduction of prices in line with evolution of ex-factory prices in six<br />

EU countries<br />

Turnover taxes of maximum e100 million if there is budget overrun<br />

(2008); <strong>crisis</strong> tax of 1% since 2010 <strong>and</strong> 0.13% since 2013<br />

Notes: INN: international non-proprietary name; a The list of measures is not exhaustive.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!